title: Guidelines on the use of intravenous immune globulin for neurologic conditions.
abstract: Canada's per capita use of intravenous immune globulin (IVIG) grew by approximately 115% between 1998 and 2006, making Canada one of the world's highest per capita users of IVIG. It is believed that most of this growth is attributable to off-label usage. To help ensure IVIG use is in keeping with an evidence-based approach to the practice of medicine, the National Advisory Committee on Blood and Blood Products (NAC) and Canadian Blood Services convened a panel of national experts to develop an evidence-based practice guideline on the use of IVIG for neurologic conditions. The mandate of the expert panel was to review evidence regarding use of IVIG for 22 neurologic conditions and formulate recommendations on IVIG use for each. A panel of 6 clinical experts, one expert in practice guideline development and 4 representatives from the NAC met to review the evidence and reach consensus on the recommendations for the use of IVIG. The primary sources used by the panel were 2 recent evidence-based reviews. Recommendations were based on interpretation of the available evidence and, where evidence was lacking, consensus of expert clinical opinion. A draft of the practice guideline was circulated to neurologists in Canada for feedback. The results of this process were reviewed by the expert panel, and modifications to the draft guideline were made where appropriate. This practice guideline will provide the NAC with a basis for making recommendations to provincial and territorial health ministries regarding IVIG use management. Recommendations for use of IVIG were made for 14 conditions, including acute disseminated encephalomyelitis, chronic inflammatory demyelinating polyneuropathy, dermatomyositis, diabetic neuropathy, Guillain-Barré syndrome, Lambert-Eaton myasthenic syndrome, multifocal motor neuropathy, multiple sclerosis, myasthenia gravis, opsoclonus-myoclonus, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, polymyositis, Rasmussen's encephalitis, and stiff person syndrome; IVIG was not recommended for 8 conditions including adrenoleukodystrophy, amyotropic lateral sclerosis, autism, critical illness polyneuropathy, inclusion body, myositis, intractable childhood epilepsy, paraproteinemic neuropathy (IgM variant), and POEMS syndrome. Development and dissemination of evidence-based clinical practice guidelines may help to facilitate appropriate use of IVIG.
authors.affiliation: IVIG Hematology and Neurology Expert Panels.
authors.forename: Tom
authors.initials: T
authors.lastname: Feasby
authors.forename: Brenda
authors.initials: B
authors.lastname: Banwell
authors.forename: Timothy
authors.initials: T
authors.lastname: Benstead
authors.forename: Vera
authors.initials: V
authors.lastname: Bril
authors.forename: Melissa
authors.initials: M
authors.lastname: Brouwers
authors.forename: Mark
authors.initials: M
authors.lastname: Freedman
authors.forename: Angelika
authors.initials: A
authors.lastname: Hahn
authors.forename: Heather
authors.initials: H
authors.lastname: Hume
authors.forename: John
authors.initials: J
authors.lastname: Freedman
authors.forename: David
authors.initials: D
authors.lastname: Pi
authors.forename: Louis
authors.initials: L
authors.lastname: Wadsworth
mesh_terms: D002170:Canada; D019317:Evidence-Based Medicine; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D009422:Nervous System Diseases / Q000188:drug therapy*; D019966:Substance-Related Disorders
chemical_list: D016756:Immunoglobulins, Intravenous